NPCE — NeuroPace, Inc.

NeuroPace (NPCE) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $22.1 million for Q1 2026, with $22 million excluding DIXI Medical, representing an 8% year-over-year growth.
• RNS System Revenue: $21.7 million, up 19.5% from $18.2 million in Q1 2025.
• Non-GAAP Gross Margin: 82.5%, slightly down from 83.6% in the prior year, but underlying gross margin improved due to favorable pricing.
• Operating Expenses: Non-GAAP operating expenses were $21.5 million, up from $19.4 million, reflecting a 10% increase, which is below revenue growth.
• Net Loss: GAAP net loss of $6.7 million, compared to a loss of $6.6 million in the prior year.
• Cash Position: Ended the quarter with $54.8 million in cash and equivalents, down from $61.2 million at year-end 2025.

2. Strategic Updates and Business Highlights

• Market Development: Continued investment in the commercial organization, including hiring sales representatives and enhancing patient navigation resources.
• Clinical Development: Productive FDA mid-cycle review for the Nautilus PMA supplement, with ongoing dialogue viewed as constructive.
• Patient Pipeline: Achieved all-time highs in active prescribers and patient pipeline, driven by comprehensive epilepsy centers and community referrals.
• AI Tools: Progress on NeuroPace AI suite, including the ECOG assistant aimed at improving clinician workflow and patient management.

3. Forward Guidance and Outlook

• Revenue Guidance: Raised full-year 2026 revenue guidance to $99 million - $101 million, up from $98 million - $100 million, reflecting 21%-23% growth in RNS revenue.
• Adjusted EBITDA: Expected loss improved to a range of $8.5 million to $9.5 million, from a previous estimate of $9 million to $10 million.
• Operational Focus: Continued emphasis on disciplined investment in R&D and commercial activities to drive long-term growth.

4. Bad News, Challenges, or Points of Concern

• Regulatory Risks: The FDA's ability to pause the review clock for additional information could delay approval timelines.
• Competitive Pressures: Other epilepsy competitors are also reporting strengthening patient funnels, indicating increased competition in the market.
• Cash Flow: A decrease in cash reserves due to typical first-quarter outflows, primarily from corporate bonuses, raises concerns about cash management.

5. Notable Q&A Insights

• Patient Pipeline Dynamics: Growth attributed to deeper market penetration and increased utilization at existing centers, along with community referrals.
• FDA Interaction: The FDA is focused on the totality of data from the Nautilus study, including secondary endpoints, which may influence labeling.
• Reimbursement Landscape: Anticipated midyear approval for IGE indication expansion, with a cautious approach to including potential revenue in guidance until approval is secured.
• Replacement Revenue: Currently, replacement revenue is minimal but expected to grow as the RNS devices reach the end of their battery life, with a long-term view on recurring revenue potential.

Overall, NeuroPace is positioned for growth with strong revenue performance and strategic initiatives, despite facing regulatory and competitive challenges.